Show simple item record

dc.contributor.authorAmeratunga, M
dc.contributor.authorHarvey, RD
dc.contributor.authorMau-Sorensen, M
dc.contributor.authorThistlethwaite, Fiona C
dc.contributor.authorForssmann, U
dc.contributor.authorGupta, M
dc.contributor.authorJohannsdottir, H
dc.contributor.authorRamirez-Andersen, T
dc.contributor.authorBohlbro, ML
dc.contributor.authorLosic, N
dc.contributor.authorErvin-Haynes, AL
dc.contributor.authorLopez, JS
dc.contributor.authorVergote, I
dc.date.accessioned2019-11-19T16:01:03Z
dc.date.available2019-11-19T16:01:03Z
dc.date.issued2019en
dc.identifier.citationAmeratunga M, Harvey RD, Mau-S�rensen M, Thistlethwaite F, Forssmann U, Gupta M, et al. First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors. J Clin Oncol. 2019;37(15_suppl):2525-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.2525en
dc.identifier.urihttp://hdl.handle.net/10541/622435
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2525en
dc.titleFirst-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumorsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Alfred Hospital, Melbourne, Australiaen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record